ReviewWorld journal of gastroenterology2023
Bone loss in chronic liver diseases: Could healthy liver be a requirement for good bone health?
Review in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Inflammatory Biomarkers Following Orthopedic Surgery: Current Evidence, Clinical Applications, and Future Perspectives-A Narrative Review.Journal of clinical medicine · 2026Review
- Bone health and chronic viral infections: A narrative literature review.World journal of virology · 2026Review
- Metabolic dysfunction-associated steatotic liver disease and bone mineral density in type 2 diabetes mellitus: insights from a single-center cross-sectional study in North India.Frontiers in endocrinology · 2026Article
- Development of a prediction model for recurrent vertebral fractures in patients two years after vertebral augmentation using noninvasive data: a retrospective study.BMC musculoskeletal disorders · 2025Article
- Perirenal fat and alcohol consumption contribute to marginal bone loss after dental implant surgery in type 2 diabetes.World journal of diabetes · 2025Article
- Mechanisms and targeted prevention of hepatic osteodystrophy caused by a low concentration of di-(2-ethylhexyl)-phthalate.Frontiers in immunology · 2025Article
- Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis.PloS one · 2025Article
- Beyond the Surface: Uncovering Secondary Causes of Osteoporosis for Optimal Management.Biomedicines · 2024Review
- Prevalence and risk factors of low bone mineral density in Chinese Han male patients with alcohol dependence.The Journal of international medical research · 2024Article
- Review
- Prediction of Osteoporotic Hip Fracture Outcome: Comparative Accuracy of 27 Immune-Inflammatory-Metabolic Markers and Related Conceptual Issues.Journal of clinical medicine · 2024Article
- Hepatocellular carcinoma and musculoskeletal system: A narrative literature review.World journal of gastroenterology · 2024Review
- Clinical Indicators of Bone Deterioration in Alcoholic Liver Cirrhosis and Chronic Alcohol Abuse: Looking beyond Bone Fracture Occurrence.Diagnostics (Basel, Switzerland) · 2024Article
- Editor-in-Chief articles of choice and comments at the year-end of 2023.World journal of gastroenterology · 2024Article
- Osteochondral lesions in Wilson's disease: case report and literature review.AME case reports · 2024Article
- Micro-scale vertebral features in postmenopausal women with alcohol-associated and metabolic-associated fatty liver disease: ex vivo bone quality analyses.Journal of endocrinological investigation · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given that the liver is involved in many metabolic mechanisms, it is not surprising that chronic liver disease (CLD) could have numerous complications. Secondary osteoporosis and increased bone fragility are frequently overlooked complications in CLD patients. Previous studies implied that up to one-third of these individuals meet diagnostic criteria for osteopenia or osteoporosis. Recent publications indicated that CLD-induced bone fragility depends on the etiology, duration, and stage of liver disease. Therefore, the increased fracture risk in CLD patients puts a severe socioeconomic burden on the health system and urgently requires more effective prevention, diagnosis, and treatment measures. The pathogenesis of CLD-induced bone loss is multifactorial and still insufficiently understood, especially considering the relative impact of increased bone resorption and reduced bone formation in these individuals. It is essential to note that inconsistent findings regarding bone mineral density measurement were previously reported in these individuals. Bone mineral density is widely used as the "golden standard" in the clinical assessment of bone fragility although it is not adequate to predict individual fracture risk. Therefore, microscale bone alterations (bone microstructure, mechanical properties, and cellular indices) were analyzed in CLD individuals. These studies further support the thesis that bone strength could be compromised in CLD individuals, implying that an individualized approach to fracture risk assessment and subsequent therapy is necessary for CLD patients. However, more well-designed studies are required to solve the bone fragility puzzle in CLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.